- $2.55bn
- $1.50bn
- $139.74m
U.S. STOCKS ON THE MOVE-Guardant Health, Hewlett Packard Enterprise, Venture Global
U.S. STOCKS ON THE MOVE-Intel, Guardant Health, CrowdStrike
U.S. STOCKS ON THE MOVE-Hims & Hers Health, Microstrategy, FedEx
Beam Therapeutics up after sickle cell therapy receives orphan drug designation
Brief: Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted To BEAM-302 For The Treatment Of Alpha-1 Antitrypsin Deficiency (AATD)
Beam Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Gene therapy makers slide on reports that FDA official Peter Marks resigns
Gene therapy makers slide on reports that FDA official Peter Marks resigns
U.S. STOCKS ON THE MOVE-GameStop, Oxford Industries, Wolfspeed
U.S. STOCKS ON THE MOVE-Camden Property Trust, Beam Therapeutics, W.R. Berkley
Beam Therapeutics rises after FDA clears genetic disorder drug application
Brief: Beam Therapeutics Announces Clearance Of Investigational New Drug Application For BEAM-302 For The Treatment Of Alpha-1 Antitrypsin Deficiency (AATD) By The United States (U.S.) Food And Drug Administration
U.S. RESEARCH ROUNDUP-Beam Therapeutics, Lennar, Redfin
Beam Therapeutics rises on early-stage trial results for gene editing therapy
Brief: Beam Therapeutics Announces Pricing Of Underwritten Offering
Brief: Beam Therapeutics BEAM-302 Was Well Tolerated At All Dose Levels
Beam Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary
Brief: Beam Therapeutics To Encore Data From Beacon Phase 1/2 Clinical Trial Of Beam-101
Brief: Beam Therapeutics Announces Progress In Hematology And Genetic Disease Franchises